Skip to main content
SpringerLink
Log in

Hormone Refractory Prostatic Cancer: The Role of Radiolabelled Diphosphonates and Growth Factor Inhibitors

  • Chapter
Prostate Cancer and Bone Metastasis

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 324))

  • 142 Accesses

Abstract

Prostate cancer responds dramatically to androgen ablative therapy. For the majority of patients, the responses are not durable, particularly in bone, and progression developed in a median of 12–18 months [1,2]. Once hormone-refractory disease becomes clinically manifest, no standard therapy exists [3], and median survival rarely exceeds one year. While the exact etiology of androgen independence is not well defined, increasing evidence suggests that autocrine and paracrine production of specific growth factors may be contributory [4]. The unique avidity of prostatic cancer cells for the skeleton, a cause of significant morbidity [5], is also partially related to the presence of specific bone marrow derived growth factors that stimulate prostatic cancer cell growth [6]. This report describes therapies directed specifically to prostatic cancer in the skeleton and to one putative growth factor inhibitor, suramin, that has recently shown activity in the hormone refractory setting.

Supported by CA-05826 and CM-01-57732 from the National Institutes of Health and a grant from Mallinckrodt, Inc., St. Louis, Mo.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. De Voogt H.J., Suciu S., Sylvester R., et al, Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials, J. Urol. 141:883–888 (1989).

    PubMed  Google Scholar 

  2. Goldenberg S.L., Bruchovsky N., Rennie P.S. and Coppin C.M., The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma, J. Urol. 140:1460–1465 (1988).

    PubMed  CAS  Google Scholar 

  3. Scher H.I., Predicting biologic potential in prostate cancer, Curr. Opin. in Oncol. 2:520–528 (1990).

    CAS  Google Scholar 

  4. Thompson T.C., Growth factors and oncogenes in prostate cancer. Cancer Cells 2:345–354 (1990).

    PubMed  CAS  Google Scholar 

  5. Scher H.I. and Yagoda A., Bone metastases: Pathogenesis, treatment and rationale for use of resorption inhibitors, Amer. J. Med. 82(supp 2A):6–28 (1987).

    Article  PubMed  CAS  Google Scholar 

  6. Chakal-Roy M., Niemeyer C., Moore M. and Zetter B.R., Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow, J. Clin. Invest. 84:43–50 (1989).

    Article  Google Scholar 

  7. Maxon H.R., Schroder L.E., Thomas S.R., et al, Radionuclide palliation of cancer-related bone pain, XVII Proceedings of the Southeastern Chapter of the The Society of Nuclear Medicine pp. 1-18 (1988).

    Google Scholar 

  8. Lattimer J.C., Corwin L.A., Stapleton J., et al. Clinical and clinipathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs, J. Nucl. Med. 31:586–593 (1990).

    PubMed  CAS  Google Scholar 

  9. Reddy E.K., Robinson R.G. and Mansfield C.M., Strontium-89 for palliation of metastasis, J. Natl. Med. Assoc. 78:27–32 (1986).

    PubMed  CAS  Google Scholar 

  10. Goeckeler W.F., Edward B., Volert W.A., et al, Skeletal localization of samarium-153 chelates: potential therapeutic bone agents J. Nucl. Med. 28:495–504 (1987).

    PubMed  Google Scholar 

  11. Ketring A.R., 153-Sm-EDTMP and 186-Re-HEDP as bone therapeutic radiopharmaceuticals, Int. J. Nucl. Med. Biol. 3:223–232 (1987).

    Google Scholar 

  12. Mathieu L., Chevalier P., Galy G. and Berger M., Preparation of 186-rhenium labelled HEDP and its possible use in the treatment of osseous neoplasms, Int. J. Appl. Radiat. Isot. 30:725–727 (1979).

    Article  PubMed  CAS  Google Scholar 

  13. Applebaum F.R., Sandmaier B., Brown P.A., et al, Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP, Antibody, Immunoconjugates and Radiopharmaceuticals 1:263–270 (1988).

    Google Scholar 

  14. Lattimer J.C., Corwin L.A., Stapleton J., et al, Clinical and clinipathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs, J. Nucl. Med. 31:1316–1325 (1990).

    PubMed  CAS  Google Scholar 

  15. Collins C., Eary J., Nemiroff C., et al, Phase I trial of samarium (SM) 153-EDTMP in hormone refractory D2 prostate carcinoma Proc. Amer. Soc. Clin. Oncol. 9:134 (1990).

    Google Scholar 

  16. Turner J.H., Claringbold P.G., Hetherington E.L., et al, A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases, J. Clin. Oncol. 7:1926–1931 (1989).

    PubMed  CAS  Google Scholar 

  17. Eisenhut M. Preparation of Re-186 perrhenate for nuclear medical purposes, Int. J. Appl. Radial. Isot. 33:99–103 (1982).

    Article  CAS  Google Scholar 

  18. Deutsch E., Libson K., Vanderheyden J., et al, The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine, Nucl. Med. Biol. 13:465–477 (1986).

    CAS  Google Scholar 

  19. Maxon H.R., Deutsch E.A., Thomas S.R., et al, Re-186(Sn)HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies, Radiology 166:501–507 (1988).

    PubMed  CAS  Google Scholar 

  20. Maxon H.R., Personal Communication (1990).

    Google Scholar 

  21. Maxon H.R., Schroder L.E., Thomas S.R., et al, 186-Re(Sn)-HEDP for the treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone resistant prostatic cancer, Radiology 176:155–159 (1990).

    PubMed  Google Scholar 

  22. Scher H.I., Phase II trial of 186-Re-HEDP for palliation of bone metastases from prostatic cancer, Memorial Hospital Protocol 89–129.

    Google Scholar 

  23. Scher H.I., Phase I trial of escalated administered activities of 186-Re-HEDP for the palliation of bone metastases from prostatic cancer, Memorial Hospital Protocol 90–129.

    Google Scholar 

  24. Scher H.I, Curley T., Yeh S., et al, Phase II of 186-Re-HEDP for the palliation of bone metastases from prostatic cancer, 3rd Tokyo Symposium on Prostatic Cancer, Tokyo, Japan, December (1990).

    Google Scholar 

  25. Myers C.E., La Rocca R., Stein C., et al, Treatment of hormonally refractory prostate cancer with suramin, Proc. Amer. Soc. Clin. Onc 9:133 (1990).

    Google Scholar 

  26. Knabbe C., Kellner C., Schmahl M., et al, Suramin inhibits growth of human prostate carcinoma cells by inactivation of growth factor action, Proc. Amer. Assoc. Cancer Res. 30:295 (1989).

    Google Scholar 

  27. Heston W.D.W., Fair W.R., Huryk R. and Russo P., Growth inhibitory effect of suramin on urologic tumors in-vitro, J. Urol. 141:729 (352A) (1989).

    Google Scholar 

  28. Kim J.H,. Sherwood E.R., Krengel S.S. and Kozlowski J.M., Cytostatic and cytotoxic effects of suramin on human prostate cancer cell lines, PC3 and DU145, J. Urol. 143:213 (1990).

    Google Scholar 

  29. Mitchen J.L., Rago R.P. and Wilding G., Effects of suramin and TGFβon the proliferation of primary epithelial culture (PEC) for normal, benign hyperplastic (BPH) and cancerous human prostates, Proc. Amer. Assoc. Cancer Res. 31:1289 (1990).

    Google Scholar 

  30. Berns E.M.J.J., Schurmans A.L.G., Bolt J., et al, Antiproliferative effects of suramin on androgen responsive tumour cells, Eur. J. Cancer 26:470–474 (1990).

    Article  PubMed  CAS  Google Scholar 

  31. Williams L., Tremble P., Lavin M., et al, Platelet-derived growth factor receptors form a high affinity state in membrane preparations, J. Biol. Chem. 259:5287–5294 (1984).

    PubMed  CAS  Google Scholar 

  32. Coffey R.J., Leof E.B., Shipley G.D., et al, Suramin inhibition of growth factor receptor biding and mitogenicity in AKR-2B cells, J. Cell. Physiol. 132:143–148 (1987).

    Article  PubMed  CAS  Google Scholar 

  33. Ashby H., DiMattina M., Linehan M., et al, The inhibition of human adrenal steroidogenic enzyme activities by suramin, J. Clin. Endocrinol Metab. 68:505–508 (1989).

    Article  PubMed  CAS  Google Scholar 

  34. W.H.O. Technical Report Series #247 W.H.O. Expert Committee on Trypanosomiasis, First Report, Geneva (1962).

    Google Scholar 

  35. Hawking F., Suramin: with special reference to onchocerciasis, Adv. Pharma. Chemother. 15:189–322 (1978).

    Google Scholar 

  36. De Clercq E., Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses, Cancer Letters 8:9–22 (1979).

    Article  PubMed  Google Scholar 

  37. Scher H.I. and Heston W.D.W., Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors, in: “Genitourinary Oncology,” Lawson H., Lepor R., eds., Martinus Nijhoff Publishers, New York (in press).

    Google Scholar 

  38. Pollak M. and Richard M., Suramin blockade of insulin like growth factor I stimulated proliferation of human osteosarcoma cells, J. Natl. Cancer Inst. 82:1349–1352 (1990).

    Article  PubMed  CAS  Google Scholar 

  39. La Rocca R.V., Danesi R., Cooper M.R., et al, Effect of suramin on human prostate cancer cells in vitro, J. Urol. 145:393–398 (1991).

    PubMed  Google Scholar 

  40. Morton R.A., Isaacs J.T. and Isaacs W.B., Differential effects of growth factor antagonists on neoplastic and normal prostatic cells, The Prostate 17:327–336 (1990).

    Article  PubMed  CAS  Google Scholar 

  41. Pienta K.J., Isaacs W.B., Vindivich D. and Coffey D.S., The effects of basic fibroblast growth factor and suramin on cell motility and growth on rat prostate cancer cells, J. Urol. 145:199–202 (1991).

    PubMed  CAS  Google Scholar 

  42. Mydlo J.H., Bulbul M.A., Richon V.M., et al, Heparin-binding growth factor isolated from human prostatic extracts, The Prostate 12:343–355 (1988).

    Article  PubMed  CAS  Google Scholar 

  43. Mydlo J.H., Michaeli J., Heston W.D.W and Fair W.R., Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma, The Prostate 13:241–247 (1988).

    Article  PubMed  CAS  Google Scholar 

  44. Story M.T., Sasse J., Jacobs S.C. and Lawson R.K., Prostatic growth factor: purification and structural relationship to basic fibroblast growth factor, Biochemistry 26:3843–3849 (1987).

    Article  PubMed  CAS  Google Scholar 

  45. Mansson P.E., Adams P., Kan M. and McKeehan W.L., Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors, Cancer Res. 49:2485–2494 (1989).

    PubMed  CAS  Google Scholar 

  46. Nishi N., Matuo Y. and Wada F., Partial purification of a major type of rat prostatic growth factors: characterization as an epidermal growth factor relative mitogen, The Prostate 13:209–220 (1988).

    Article  PubMed  CAS  Google Scholar 

  47. Mori H., Maki M., Oishi K., et al, Increased expression of genes for fibroblast growth factor and transforming growth factor B-2 in human benign prostatic hyperplasia, Prostate 13:241–247 (1990).

    Google Scholar 

  48. Wilding G., Valverius E., Knabbe C. and Gelmann E.P., Role of transforming growth factor alpha in human prostate cancer cell growth, The Prostate 15:1–12 (1989).

    Article  PubMed  CAS  Google Scholar 

  49. Connolly J.M. and Rose D.P., Production of epidermal growth factor and transforming growth factor alpha by the androgen-responsive LNCaP human prostate cancer cell line, The Prostate 16:209–218 (1990).

    Article  PubMed  CAS  Google Scholar 

  50. Hofer D.R., Sherwood E.R., Bromberg W.D., et al, The functional role of transforming growth factor alpha as an autocrine growth factor in androgen-independent human prostatic carcinoma (In press).

    Google Scholar 

  51. Martikainen P., Kyprianou N. and Isaacs J.T., Effect of transforming growth factor-β 1 on proliferation and death of rat prostatic cells, Endocrinol. 127:2963–2968 (1990).

    Article  CAS  Google Scholar 

  52. Peehl D.M., Wong S.T. and Stamey T.A., Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors, J. Urol. 145:624–627 (1991).

    PubMed  CAS  Google Scholar 

  53. Collins J., Klecker R.J., Yarchoan R., et al, Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection, J. Clin. Pharmacol. 26:22–26 (1986).

    PubMed  CAS  Google Scholar 

  54. Ono K., Nakara H. and Fukushima M., Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin, Eur. J. Biochem. 172:349–353 (1988).

    Article  PubMed  CAS  Google Scholar 

  55. Moriyana Y. and Nelson N., Inhibition of vacuolar H+-ATPases by fusidic acid and suramin, Febs. Lett. 234:383–386 (1988).

    Article  Google Scholar 

  56. Hensey C.E., Boscoboinik D. and Azzi A., Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A, FEBS. LETT. 258:156–158 (1989).

    Article  PubMed  CAS  Google Scholar 

  57. Fantini J., Rognoni J.B., Roccabianca M., et al, Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colonic adenocarcinoma cell clone HT-29-D4, J. Biol. Chem. 264:10282–10286 (1989).

    PubMed  CAS  Google Scholar 

  58. Fantini J., Verrier B., Robert C., et al, Suramin-induced differentiation of human colonic adenocarcinoma cell clone HT29-D4 in serum free medium, Exp. Cell. Res. 89:109–117 (1990).

    Article  Google Scholar 

  59. Constantopoulos G., Rees S., Cragg B.G., et al, Effect of suramin on degradative enzymes of sphingolipids in rats, Res. Commun. Chem. Pathol. Pharmacol. 32:87–97 (1981).

    PubMed  CAS  Google Scholar 

  60. Constantopoulos G., Rees S., Cragg B.G., et al, Experimental animal model for mucopolysaccharidosis: suramin induced glycosaminoglycan and sphingolipids accumulation in rat, Proc. Natl. Acad. Sci. (USA) 77:3700–3704 (1980).

    Article  CAS  Google Scholar 

  61. Cooper M., La Rocca R., Stein C. and Myers C., Pharmacokinetic monitoring is necessary for the safe use of suramin as an anticancer drug, Proc. Amer. Assoc. Cancer Res. 30:242 (963) (1989).

    Google Scholar 

  62. La Rocca R.V., Meer J., Gilliat R.W., et al, Suramin-induced polyneuropathy, Neurology 40:954–960 (1990).

    Article  PubMed  Google Scholar 

  63. Home M.V., Stein C.Y., La Rocca R.V. and Myers C.E., Circulating glycosaminoglycans anticoagulants associated with suramin treatment, Blood 71:273–279 (1988).

    Google Scholar 

  64. Holland E.J., Stein C.A., Palestine A.G., et al. Suramin keratopathy. Amer J Opthal 106:216–221, (1988).

    CAS  Google Scholar 

  65. Weiss G.H., Jamis-Dow C.A., Cooper M.R., Linehan W.M. and Myers C.E., Pharmacokinetics and biodistribution of suramin, J. Urol. 143:218 (243A) (1990).

    Google Scholar 

  66. Stein C.A., La Rocca R. and Myers C., Suramin: An old compound with new biology, Prin. and Pract. of Oncol. May (1990).

    Google Scholar 

  67. Ahmann F.R., Schwartz J., Dorr R., and Salmon S., Suramin in hormone resistant metastatic prostate cancer: significant anticancer activity but unanticipated toxicity, Proc. Amer. Soc. Clin. Oncol. 10: (in press) (1991).

    Google Scholar 

  68. Senderowicz A., Scher H., Gordon M., et al, Infectious complications of suramin in patients with genitourinary tumors, Proc. Amer. Assoc. Cancer Res. 32: (in press) (1991).

    Google Scholar 

  69. Stein C.A., La Rocca R., McAtee N., et al, Suramin-an anti-cancer drug with a unique mechanism of action, J. Clin. Oncol. 7:499–508 (1988).

    Google Scholar 

  70. Myers C.E., La Rocca R., Stein C., et al, Treatment of hormonally refractory prostate cancer with suramin, Proc. Amer. Soc. Clin. Onc. 9:133 (517) (1990).

    Google Scholar 

  71. Cooper M., La Rocca R., Stein C. and Myers C., Pharmacokinetic monitoring is necessary for the safe use of suramin as an anticancer drug, Proc. Amer. Assoc. Cancer Res. 30:242 (1989).

    Google Scholar 

  72. Christian M., T89-0084, Phase II trial of suramin in hormone refractory prostatic cancer, Personal communication (1991).

    Google Scholar 

  73. Forrest A., Scher H.I., Tong W., et al, Development of an adaptive control algorithm for suramin, Proc. Am. Soc. Clin. Oncol. 9:73 (Abst# 284) (1990).

    Google Scholar 

  74. D’Argenio D.Z., and Schumitzky A., Adapt II, Biomedical Simulations Resource, U.S.C., Los Angeles (1990).

    Google Scholar 

  75. Drusano G.L., Forrest A., Snyder M.J., Reed M.D. and Blumer J.L., An evaluation of optimal sampling strategy and adaptive study design, Clin. Pharmacol. Ther. 44:232–238 (1988).

    Article  PubMed  CAS  Google Scholar 

  76. Eisenberger M., Jodrell D., Sinibaldi V., et al, Preliminary evidence of anti-tumor activity against prostate cancer (PrCa) observed in a phase I trial with suramin, Proc. Amer. Soc. Clin. Oncol. 10: (in press) (1991).

    Google Scholar 

  77. Scher H.I. (Principal Investigator), Phase I trial of suramin in advanced cancer, Memorial Hospital Protocol 50–90.

    Google Scholar 

  78. Tong W.P., Scher H.I., Petrylak D.P., et al, A rapid assay of suramin in plasma, J. Liquid Chromatogr. 13:2269–2284 (1990).

    Article  CAS  Google Scholar 

  79. Scher H.I., Curley T., Geller N., et al, Trimetrexate in prostatic cancer: preliminary observations of the use of prostate specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease, J. Clin. Oncol. 8:1830–1838 (1990).

    PubMed  CAS  Google Scholar 

  80. Gerber G.S. and Chodak G.W., Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastastic prostate cancer, J. Urol. 144:1177–1178 (1990).

    PubMed  CAS  Google Scholar 

  81. Scher H.I. and Nisselbaum J., (Unpublished observations) (1990).

    Google Scholar 

  82. Petrylak D.P., Scher H.I., Lin S., et al, Prognostic factors for survival of patients treated with singleagent chemotherapy bidimensionally measurable hormone refractory metastatic prostatic cancer. (Submitted for publication).

    Google Scholar 

  83. Tannock I., Gospodarowicz M., Meakin W., Panzarella T., Stewart L. and Rider W., Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response, J. Clin. Oncol. 7:590–597 (1990).

    Google Scholar 

  84. Freuhof J.P., Myers C.E. and Sinha B.K., Synergistic activity of suramin with tumor necrosis factor A and doxorubicin on human prostate cancer cell lines, J. Natl. Cancer Inst. 82:1206–1209 (1990).

    Article  Google Scholar 

  85. Phase II trial of suramin in bidimensionally measurable hormone refractory prostatic cancer (MSKCC results).

    Google Scholar 

  86. Dawson, N., Walter Reed Medical Center, Personal communication (1990).

    Google Scholar 

  87. Van Oosterom A.T., De Simedt E.A., Denis J. J., et al, Suramin for prostatic cancer: A phase I/II study in advanced extensively pretreated disease, Eur. J. Cancer 26:422 (1990).

    Article  PubMed  Google Scholar 

  88. Armand J.P. and Droz J.P., Institute Gustave-Roussy, Personal communication (1991).

    Google Scholar 

  89. Rapoport B.L., Ansell S., Coccia-Portugal M.A., et al, Phase II clinical study of suramin in combination with mitomycin-C in patients with hormone refractory prostate cancer, Proc. Amer. Soc. Clin. Oncol. 10:(in press) (1991).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Solid Tumor Oncology Department of Medicine, Genitourinary Oncology Service, USA

    Howard I. Scher & Tracy Curley

  2. Division of Nuclear Medicine, Program of Molecular Pharmacology and Therapeutics Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY, 10021, USA

    Samuel Yeh & Steven Larson

  3. Division of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY, 10021, USA

    William Tong

  4. Division of Diagnostic Radiology Department of Medical Imaging, USA

    Paul V. O’Moore

  5. Department of Medicine, Cornell University Medical College, New York, NY, USA

    Howard I. Scher

Authors
  1. Howard I. Scher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tracy Curley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samuel Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul V. O’Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven Larson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Roswell Park Cancer Institute, Buffalo, New York, USA

    James P. Karr

  2. Gunma University, Gunma, Japan

    Hidetoshi Yamanaka

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Scher, H.I., Curley, T., Yeh, S., Tong, W., O’Moore, P.V., Larson, S. (1992). Hormone Refractory Prostatic Cancer: The Role of Radiolabelled Diphosphonates and Growth Factor Inhibitors. In: Karr, J.P., Yamanaka, H. (eds) Prostate Cancer and Bone Metastasis. Advances in Experimental Medicine and Biology, vol 324. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3398-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3398-6_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6501-3

  • Online ISBN: 978-1-4615-3398-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation